Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Franziska AuerTechnical University of Munich, Germany; School of Medicine and Health; Department of Pediatrics, Munich, Germany.ORCID 0000-0002-1193-6002
Mina N F MorcosTechnical University of Munich, Germany; School of Medicine and Health; Department of Pediatrics, Munich, Germany.ORCID 0000-0001-5812-9526
Mikko SipolaInstitute of Biomedicine, School of Medicine, University of Eastern Finland, Yliopistonranta 8, FI-70211, Kuopio, Finland.
Irfan AkhtarTechnical University of Munich, Germany; School of Medicine and Health; Department of Pediatrics, Munich, Germany.ORCID 0000-0003-1566-2755
Sanni MoisioInstitute of Biomedicine, School of Medicine, University of Eastern Finland, Yliopistonranta 8, FI-70211, Kuopio, Finland.ORCID 0009-0009-4446-015X
Julia VogtTechnical University of Munich, Germany; School of Medicine and Health; Department of Pediatrics, Munich, Germany.ORCID 0009-0005-4011-1084
Rebecca HaagTechnical University of Munich, Germany; School of Medicine and Health; Department of Pediatrics, Munich, Germany.ORCID 0000-0001-9575-9471
Mari LahnalampiInstitute of Biomedicine, School of Medicine, University of Eastern Finland, Yliopistonranta 8, FI-70211, Kuopio, Finland.ORCID 0000-0003-4050-4935
Tiina J TuononenInstitute of Biomedicine, School of Medicine, University of Eastern Finland, Yliopistonranta 8, FI-70211, Kuopio, Finland.
Andrea HanelInstitute of Biomedicine, School of Medicine, University of Eastern Finland, Yliopistonranta 8, FI-70211, Kuopio, Finland.
Anna ViitasaloInstitute of Biomedicine, School of Medicine, University of Eastern Finland, Yliopistonranta 8, FI-70211, Kuopio, Finland.
Ulrike A FriedrichDRESDEN-concept Genome Center, Technology Platform at the Center for Molecular and Cellular Bioengineering (CMCB), Dresden University of Technology (TUD), Dresden, Germany.ORCID 0000-0001-7295-4549
Andreas DahlDRESDEN-concept Genome Center, Technology Platform at the Center for Molecular and Cellular Bioengineering (CMCB), Dresden University of Technology (TUD), Dresden, Germany.ORCID 0000-0002-2668-8371
Carolin PrexlerTechnical University of Munich, Germany; School of Medicine and Health; Department of Pediatrics, Munich, Germany.ORCID 0000-0001-7136-0554
Aleksandra A PandyraInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.ORCID 0000-0003-4794-0035
Polina StepenskyDepartment of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Masatoshi TakagiDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo, Japan.ORCID 0000-0002-7580-9184
Arndt BorkhardtDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Duesseldorf, Medical Faculty, Duesseldorf, Germany.ORCID 0000-0002-6121-4737
Merja Heinäniemi *Institute of Biomedicine, School of Medicine, University of Eastern Finland, Yliopistonranta 8, FI-70211, Kuopio, Finland. merja.heinaniemi@uef.fi.
Julia Hauer *Technical University of Munich, Germany; School of Medicine and Health; Department of Pediatrics, Munich, Germany. Julia.Hauer@mri.tum.de.ORCID 0000-0002-4058-3058
Funding
Deutsche Forschungsgemeinschaft (German Research Foundation) 547295412Deutsche Krebshilfe (German Cancer Aid) 70114539EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) Stg 85222José Carreras Leukämie-Stiftung (Deutsche José Carreras Leukämie-Stiftung) DJCLS 18R/2021Sigrid Juséliuksen Säätiö (Sigrid Jusélius Foundation) 341693
6 · The paper itself
Abstract
PAX5 acts as a master regulator of B-cell proliferation and differentiation. Its germline and somatic deregulation have both been implicated in the development of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, the process how reduced PAX5 transcriptional activity mediates progression to BCP-ALL, is still poorly understood. Here, we characterized the longitudinal effects of PAX5 reduction on healthy, pre-leukemic and BCP-ALL cells at the single-cell level. Cell-surface marker analysis revealed a genotype-driven enrichment of the pre-BII population in healthy Pax5
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo. · full record | OpenQuestion